Publications by authors named "Peter B Gilbert"

Claim this Profile
U
Unbiased cell clustering analysis of vaccine-induced T cell responses in the Imbokodo HIV-1 vaccine trial.
Valentin Voillet, Janine van Duijn, Kanika Vanshylla, One B Dintwe, Laura Pattacini, Peter B Gilbert

EBioMedicine· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial.
Susan P Buchbinder, Sabrina Spinosa Guzman, Jorge Sanchez, Wouter Willems, Daniel J Stieh, Peter B Gilbert

Lancet HIV· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Viral correlates of protection and the multifarious interactions of B and T cells.
H Cody Meissner, Peter B Gilbert, Derek Eisnor, Daniel N Wolfe

Hum Vaccin Immunother· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving the evidence base for COVID-19 vaccines.
Helen Y Chu, Holly Janes, Marco Carone, Peter B Gilbert, Stanley Plotkin

Nat Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Correlates and Vaccine Immunobridging: Statistical Innovations, Challenges, and Opportunities.
Marco Carone, Charles J Wolock, Antonio Olivas-Martinez, Andrea Rotnitzky, Peter B Gilbert

J Infect Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy.
Lutz Gieselmann, Andrew T DeLaitsch, Malena Rohde, Henning Gruell, Christoph Kreer, Peter B Gilbert

Nat Immunol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune correlates analysis of antibody responses against SARS-CoV-2 variants in the ENSEMBLE vaccine efficacy trial.
Alex Luedtke, Youyi Fong, Lars van der Laan, Fei Heng, Ying Huang, Peter B Gilbert

iScience· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure Proximal Design but Requires Far Fewer Blood Samples.
Dean Follmann, Lauren Dang, Eric Chu, Jonathan Fintzi, Holly Janes, Peter B Gilbert

J Infect Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bayesian estimation of HIV acquisition dates for prevention trials.
Raabya Rossenkhan, Elena E Giorgi, Danica Shao, James Ludwig, Phillip Labuschagne, Peter B Gilbert

mBio· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trial.
David J Diemert, Daniel S Graciaa, Bo Zhang, Nadine G Rouphael, Angela R Branche, Peter B Gilbert

Vaccine· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV.
Nonhlanhla N Mkhize, Bo Zhang, Caroline Brackett, Peter James Elyanu, Asa Tapley, Peter B Gilbert

Nat Commun· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A SARS-CoV-2 variant‑adjusted threshold of protection model for monoclonal antibody pre-exposure prophylaxis against COVID-19.
Rhiannon Edge, Sam Matthews, Bahar Ahani, Anastasia A Aksyuk, Lindsay Clegg, Peter B Gilbert

Nat Commun· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of antibody markers as immune correlates of risk of severe COVID-19 in the PREVENT-19 efficacy trial of the NVX-CoV2373 recombinant protein vaccine.
Youyi Fong, Yunda Huang, Ying Huang, Wayne Woo, Alice McGarry, Peter B Gilbert

Clin Infect Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generalized nonparametric temporal modeling of recurrent events with application to a malaria vaccine trial.
Fei Heng, Yanqing Sun, Jing Xu, Peter B Gilbert

Biometrics· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention Trials.
Carolyn Williamson, Lyle Curry, Nonhlanhla N Mkhize, Elena E Giorgi, Craig A Magaret, Peter B Gilbert

bioRxiv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Read Deep Sequencing Reveals High Rates of Multilineage Transmission and Rapid Viral Population Changes in Acute HIV Infection.
James I Mullins, Wenjie Deng, Elena E Giorgi, Craig A Magaret, Morgane Rolland, Peter B Gilbert

bioRxiv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to 'Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study'. EBioMedicine 2024;108: 105320.
Avi Kenny, Janine van Duijn, One Dintwe, Jack Heptinstall, Randy Burnham, Peter B Gilbert

EBioMedicine· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validating and leveraging non-SARS-CoV-2 respiratory infection as a negative control outcome in a phase 3 COVID-19 vaccine trial with extended observational follow-up.
Ethan Ashby, Holly Janes, Dean Follmann, Peter B Gilbert, Honghong Zhou

Am J Epidemiol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Profiling a large HIV-1 elite neutralizer cohort reveals remarkable CD4bs bNAb for HIV-1 prevention and therapy.
Lutz Gieselmann, Andrew T DeLaitsch, Malena Rohde, Henning Gruell, Christoph Kreer, Peter B Gilbert

bioRxiv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling study.
Yunda Huang, Lily Zhang, Huub Gelderblom, Kelly E Seaton, Nicole L Yates, Peter B Gilbert

EBioMedicine· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials.
Carolyn Williamson, Chivonne Moodley, Craig A Magaret, Elena E Giorgi, Morgane Rolland, Peter B Gilbert

bioRxiv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data: A Secondary Cross-Protocol Analysis of 5 Randomized Clinical Trials.
Leah I B Andrews, M Elizabeth Halloran, Kathleen M Neuzil, Lars van der Laan, Yunda Huang, Peter B Gilbert

JAMA Netw Open· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addressing confounding and continuous exposure measurement error using corrected score functions.
Brian D Richardson, Bryan S Blette, Peter B Gilbert, Michael G Hudgens

Biometrics· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Data fusion using weakly aligned sources.
Sijia Li, Peter B Gilbert, Rui Duan, Alex Luedtke

J Am Stat Assoc· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A surrogate endpoint-based provisional approval causal roadmap, illustrated by vaccine development.
Peter B Gilbert, James Peng, Larry Han, Theis Lange, Yun Lu

Biostatistics· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis